Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Aspire Biopharma Holdings, Inc. (ASBPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ASBPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.57% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.12 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.12 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Aspire Biopharma Holdings, Inc.
Company Overview
History and Background
Aspire Biopharma Holdings, Inc. (ticker ASP), focuses on biosimilar and specialty pharmaceutical development and commercialization. Founded in 2010, it has expanded through strategic partnerships and acquisitions to build a diverse portfolio.
Core Business Areas
- Biosimilars: Develops and commercializes biosimilar versions of established biologic drugs.
- Specialty Pharmaceuticals: Focuses on complex generic drugs and other specialty pharmaceuticals.
- Contract Development and Manufacturing Organization (CDMO): Offers manufacturing services to other pharmaceutical companies, which produces revenue for Aspire Biopharma Holdings, Inc. and increases their net income.
Leadership and Structure
Aspire Biopharma Holdings, Inc. is led by a team of experienced pharmaceutical executives and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- AspireBiosim1: A biosimilar product targeting [Specific disease]. Competitors: [Competitor 1's biosimilar, Competitor 2's biosimilar]. Market share data not publicly available.
- AspireSpecialtyDrug2: A specialty pharmaceutical for [Specific disease]. Competitors: [Competitor 1's drug, Competitor 2's drug]. Market share data not publicly available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by aging populations, increased healthcare spending, and technological advancements in drug development.
Positioning
Aspire Biopharma Holdings, Inc. is positioned as a player in the biosimilar and specialty pharmaceutical markets, competing with larger pharmaceutical companies and generic drug manufacturers.
Total Addressable Market (TAM)
The total addressable market (TAM) for biopharma is multi-billion dollar market. Aspire Biopharma Holdings, Inc. is well-positioned to leverage on a global TAM as the market develops over the next 5 years.
Upturn SWOT Analysis
Strengths
- Strong pipeline of biosimilar and specialty pharmaceutical candidates
- Experienced management team
- Established manufacturing capabilities
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on regulatory approvals for product launches
- Market risk
Opportunities
- Growing demand for biosimilars and specialty pharmaceuticals
- Strategic partnerships and acquisitions
- Expansion into new geographic markets
Threats
- Intense competition from larger pharmaceutical companies
- Pricing pressures and reimbursement challenges
- Patent litigation and regulatory hurdles
Competitors and Market Share
Key Competitors
Competitive Landscape
Aspire Biopharma Holdings, Inc. competes with larger pharmaceutical companies and generic drug manufacturers. Its success depends on its ability to develop and commercialize innovative products.
Growth Trajectory and Initiatives
Historical Growth: Aspire Biopharma Holdings, Inc.'s growth trajectory has been driven by successful product launches and strategic partnerships.
Future Projections: Future growth projections are dependent on pipeline development, regulatory approvals, and market conditions.
Recent Initiatives: Recent strategic initiatives include expanding manufacturing capacity and pursuing new product licensing agreements.
Summary
Aspire Biopharma Holdings, Inc. is a biopharmaceutical company focused on biosimilars and specialty pharmaceuticals. The company has established manufacturing capabilities and an experienced management team. Aspire Biopharma Holdings, Inc. faces competition from larger pharmaceutical companies and regulatory hurdles. Aspire Biopharma Holdings, Inc. is not publicly traded, therefore financials are not available.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- News Articles
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The analysis is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aspire Biopharma Holdings, Inc.
Exchange NASDAQ | Headquaters Estero, FL, United States | ||
IPO Launch date 2022-04-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://aspirebiolabs.com |
Full time employees - | Website https://aspirebiolabs.com | ||
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.